Sandoz Group AG
SIX:SDZ
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
25.48
40.62
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CHF.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Sandoz Group AG
Non-Reccuring Items
Sandoz Group AG
Non-Reccuring Items Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Non-Reccuring Items | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
S
|
Sandoz Group AG
SIX:SDZ
|
Non-Reccuring Items
-$891m
|
CAGR 3-Years
7%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Novartis AG
SIX:NOVN
|
Non-Reccuring Items
-$1.7B
|
CAGR 3-Years
-22%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
N/A
|
|
|
Roche Holding AG
SIX:ROG
|
Non-Reccuring Items
-CHf3.4B
|
CAGR 3-Years
-97%
|
CAGR 5-Years
3%
|
CAGR 10-Years
-13%
|
|
Sandoz Group AG
Glance View
Sandoz Group AG, a renowned player in the pharmaceutical industry, stands as a global leader in the production of generic drugs and biosimilars. Originally part of the Swiss corporate giant Novartis, Sandoz has cultivated a reputation for delivering affordable healthcare solutions across the globe. Its foundation lies in the manufacturing of cost-effective, high-quality alternatives to branded medicines, making healthcare more accessible to a broader public. By focusing on generic pharmaceuticals—drugs that are comparable to branded products in terms of dosage, safety, strength, quality, and performance—Sandoz effectively manages to carve out a vital niche in the healthcare ecosystem. This strategic emphasis allows the company to offer a vast portfolio that spans across major therapeutic areas such as cardiovascular, central nervous system, pain management, and oncology, to name a few. Sandoz's business model hinges on its ability to streamline production processes and efficiently navigate regulatory landscapes, which enables the company to sell its products at competitive prices while maintaining profitability. One critical aspect of their operation is the capability to innovate within the generic space, exemplified by their expansion into biosimilars—biopharmaceutical drugs that are highly akin to existing biological products. As patents for major biologics expire, Sandoz capitalizes on the opportunity to introduce biosimilars, thus broadening access to complex therapies. The company invests significantly in research and development to enhance its pipeline of generic drugs and biosimilars, ensuring a steady flow of new market entries. Through a combination of strategic pricing, diverse product offerings, and robust R&D efforts, Sandoz sustains its business model while contributing profoundly to global health, embodying a mission of "Pioneering Access for Patients."
See Also
What is Sandoz Group AG's Non-Reccuring Items?
Non-Reccuring Items
-891m
USD
Based on the financial report for Dec 31, 2023, Sandoz Group AG's Non-Reccuring Items amounts to -891m USD.
What is Sandoz Group AG's Non-Reccuring Items growth rate?
Non-Reccuring Items CAGR 3Y
7%
Over the last year, the Non-Reccuring Items growth was -164%. The average annual Non-Reccuring Items growth rates for Sandoz Group AG have been 7% over the past three years .
You don't have any saved screeners yet
